A Population Pharmacokinetic and Pharmacodynamic Modelling Approach to Support the Clinical Development of RBP-6000, a New, Subcutaneously Injectable, Long-Acting, Sustained-Release Formulation of Buprenorphine, for the Treatment of Opioid Dependence

被引：0
作者：
Azmi F. Nasser
Christian Heidbreder
Roberto Gomeni
Paul J. Fudala
Bo Zheng
Mark K. Greenwald
机构：
[1] Reckitt Benckiser Pharmaceuticals Inc.,
[2] Alleantis,undefined
[3] Wayne State University,undefined
来源：
Clinical Pharmacokinetics | 2014年 / 53卷
关键词：
Buprenorphine; Withdrawal Symptom; Hydromorphone; Opioid Dependence; Objective Function Value;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：813 / 824
页数：11
相关论文
共 39 条
  • [1] Katz NP(2013)Prescription opioid abuse: challenges and opportunities for payers Am J Manag Care. 19 295-302
  • [2] Katz NP(2007)Foundations of opioid risk management Clin J Pain. 23 103-118
  • [3] Paulozzi LJ(2006)Opioid analgesics and rates of fatal drug poisoning in the United States Am J Prev Med. 31 506-511
  • [4] Ryan GW(2011)Deaths: preliminary data for 2009 Natl Vital Stat Rep. 59 1-51
  • [5] Kochanek KD(1994)Clinical pharmacology of buprenorphine: ceiling effects at high doses Clin Pharm Ther 55 569-580
  • [6] Xu J(2004)Adherence to pharmacotherapy in patients with alcohol and opioid dependence Addiction. 99 1382-1392
  • [7] Murphy SL(2007)Buprenorphine for the treatment of opioid dependence Am J Health-Syst Pharm. 64 266-272
  • [8] Miniño AM(1999)Xpose—an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM Comput Meth Prog Biomed 58 51-64
  • [9] Kung H-C(2005)PsN-Toolkit—a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM Comput Meth Prog Biomed. 79 241-257
  • [10] Walsh SL(2007)Conditional weighted residuals (CWRES): a model diagnostic for the FOCE method Pharm Res. 24 2187-2197
1234